focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
https://www.google.co.uk/search?safe=active&q=ulvr+share+price&oq=ULVR+share+&gs_l=psy-ab.1.0.0i131k1j0l6j0i22i30k1l3.9277.33192.0.40875.27.22.0.0.0.0.247.2433.4j14j2.21.0....0...1.1.64.psy-ab..9.18.2296.6..35i39k1j0i20i263k1j0i67k1.139.JItfcVjlHYU don't get your fingers burnt , sp may drop a lot further yet
The 25 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,700.00, with a high estimate of 2,100.00 and a low estimate of 1,250.00. The median estimate represents a 16.92% increase from the last price of 1,454.00.
GlaxoSmithKline plc 10.5% Potential Upside Indicated by Deutsche Bank Posted by: Amilia Stone 21st September 2017 http://www.***************************/glaxosmithkline-plc-10-5-potential-upside-indicated-by-deutsche-bank/412735839
GlaxoSmithKline, alongside Innoviva, announced on Tuesday that the US Food and Drug Administration has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
, investors can snap up shares in the firm at a rock bottom valuation. Indeed, as noted above, shares in Glaxo are currently trading at a forward P/E of 13.3, 26% below the global pharmaceutical sector median valuation of 18. PRICE THEN WAS AROUND 1475 AND AT PRESENT PRICE 1454 THERE A GOOD INCOME INVESTMENT ( OVER SOLD)
Issued: London UK – LSE GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone furoate/ umeclidinium/vilanterol (FF/UMEC/VI) as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptom control see section 5.1). The proposed brand name is Trelegy Ellipta. 13 September 2017 FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over Issued: London UK – LSE GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA. 12 September 2017 GSK announces phase III results published in NEJM of mepolizumab in patients with eosinophilic COPD at risk of exacerbations - Regulatory filings planned for 2017 Issued: London, UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the publication of full results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease (COPD). Data from the investigational clinical development programme showed that treating eosinophilic COPD patients with the biologic medicine, mepolizumab, in addition to maximal guideline-recommended therapy, reduced exacerbations in these difficult-to-treat patients. Based on the full data, discussions with external experts and the recognised unmet medical need in this patient population, regulatory filings are planned for 2017. Mepolizumab is not approved for use anywhere in the world for COPD. 11 September 2017 Positive results from pioneering Salford Lung Study in asthma published in The Lancet, and presented at European Respiratory Congress Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study. Issued: London SEPTEMBER 2017 GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study (SLS) in asthma have been simultaneously published in The Lancet journal and presented at the European Respiratory Society (ERS) International Congress in Milan. The innovative study, which reported headline results in May 2017, showed that initiation of once-daily Relvar Ellipta (fluticasone furoate ‘FF’/vila
We appreciate that results are backward looking and that medium term guidance is inspirational rather than hard fact, but Redrow had a record forward order book up 14% at £1.1bn. This suggests to us that performance is still climbing rather than reaching a plateau."
MARK WILSON INTERVIEW 2016 RESULTS https://www.aviva.com/media/video-interviews/2016-full-year-results-interview-group-ceo-mark-wilson/
In the first half of 2017, Aviva has grown operating profit, maintained capital strength and delivered on its strategic agenda. Operating profit increased 11% to £1,465 million (HY16: £1,325 million), underlining the quality of our franchises and the benefits of our product and geographic diversity. Operating earnings per share (EPS) increased 15% to 25.8p (HY16: 22.4p). Our Solvency II coverage ratio increased to 193%1 (FY16: 189%) and remains above our 150% to 180% working range. Operating capital generation was £1.1 billion (HY16: £1.2 billion) and cash remittances rose 56% to £1,170 million (HY16: £752 million). We have increased our interim dividend by 13% to 8.4p per share (HY16: 7.42p). Capital reallocation initiatives continued in the first half of 2017. We announced the withdrawal of capital from Spain and the sale of the Friends Provident International business and acquired a 100% interest in our Vietnamese venture with VietinBank. We also commenced a £300 million share buy-back programme. We have extended our track record of growth while maintaining a disciplined approach to capital allocation. Our performance in the first half of 2017 reflects the foundations built over recent years and we continue to invest in our businesses to secure consistent growth in the future
https://www.aviva.com/media/news/item/aviva-to-sell-italian-joint-venture-to-banco-bpm-17816/
i think caused by PROVIDENT FINANCIAL PLC share price collapsing 68.88% at 4pm PFG Provident Financial plc 541.75 -1,202.00 -68.88% in which EDIN has a 3.64% holding as part of it's fund the point is will PFG make a recovery doubtful i think
GlaxoSmithKline plc 5.1% Potential Upside Indicated by Deutsche Bank Posted by: Amilia Stone 7th August 2017 GlaxoSmithKline plc using EPIC/TICKER code (LON:GSK) has had its stock rating noted as ‘Retains’ with the recommendation being set at ‘HOLD’ this morning by analysts at Deutsche Bank. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 1610 GBX on its stock. This is indicating the analyst believes there is a potential upside of 5.1% from the opening price of 1532.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 83.5 points and decreased 54.5 points respectively. The 1 year high stock price is 1745.56 GBX while the 52 week low for the share price is 1446.5 GBX. GlaxoSmithKline plc has a 50 day moving average of 1,649.13 GBX and a 200 day moving average of 1,612.85. There are currently 4,918,478,488 shares in issue with the average daily volume traded being 6,510,676. Market capitalisation for LON:GSK is £75,400,275,221 GBP. GlaxoSmithKline plc 8.4% Potential Upside Indicated by Deutsche Bank Posted by: Amilia Stone 26th July 2017 GlaxoSmithKline plc with EPIC/TICKER (LON:GSK) has had its stock rating noted as ‘Retains’ with the recommendation being set at ‘HOLD’ this morning by analysts at Deutsche Bank. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 1720 GBX on its stock. This indicates the analyst now believes there is a potential upside of 8.4% from today’s opening price of 1586 GBX. Over the last 30 and 90 trading days the company share price has decreased 125 points and increased 20 points respectively. The 52 week high share price is 1745.56 GBX while the year low stock price is currently 1446.5 GBX. GlaxoSmithKline plc has a 50 day moving average of 1,667.30 GBX and the 200 Day Moving Average price is recorded at 1,617.70. There are currently 4,918,418,033 shares in issue with the average daily volume traded being 7,246,087. Market capitalisation for LON:GSK is £78,866,833,159 GBP. GlaxoSmithKline plc 17.9% Potential Upside Indicated by Goldman Sachs Posted by: Amilia Stone 20th July 2017 GlaxoSmithKline plc with EPIC/TICKER (LON:GSK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Goldman Sachs. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Goldman Sachs have set a target price of 1900 GBX on its stock. This is indicating the analyst believes there is a potential upside of 17.9% from the opening price of 1611 GBX. Over the last 30 and 90 trading days the company share price has decreased 82 points and increased 42 points respectively. The 52 week high for the stock is 1745.56 G
THE CLOSE PRICE TODAY WILL BE ADJUSTED FOR OVER NIGHT ADJUSTMENTS ,AS TODAY CLOSED TUESDAY 1534.00 OPENED TODAY 1525.00 DROPPED 9P THEN BEFORE OPENING THE SHARE PRICE WILL BE ADJUSTED AGAIN DOWN BY THE DIVIDEND PAYMENT 19P SO IT'S POSSIBLE YOU COULD SEE 1480 GOING ON THE PRICE AT THE MOMENT. OR ON THE OVER HAND YOU COULD SEE THE OVER NIGHT PRICE SHOOT UP BY 9P BUT DON'T BET ON IT.
AstraZeneca's lung cancer drug trial setback is "not the end of the story but as good as", broker Jefferies has commented this afternoon. The blow removes around 10-15pc of its mid-term earnings and valuation, it said. However, it added that the company "still has a number of other interesting pipelines" and other assets that will support its share price in the future once the impact of MYSTIC has been priced in.
On the upside for AstraZeneca, net profit soared 58% to $1.01bn after steep cost-cutting in the first six months of 2017. Remember https://www.youtube.com/watch?v=SJUhlRoBL8M